Astrazeneca Pharma India Ltd banner

Astrazeneca Pharma India Ltd
NSE:ASTRAZEN

Watchlist Manager
Astrazeneca Pharma India Ltd Logo
Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
Watchlist
Price: 8 452 INR -0.93% Market Closed
Market Cap: ₹211.3B

Astrazeneca Pharma India Ltd
Other Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Astrazeneca Pharma India Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
Other Current Liabilities
₹2.2B
CAGR 3-Years
15%
CAGR 5-Years
13%
CAGR 10-Years
4%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Other Current Liabilities
₹68.8B
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Other Current Liabilities
₹30.9B
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
15%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Other Current Liabilities
₹118.6B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
7%
Lupin Ltd
NSE:LUPIN
Other Current Liabilities
₹30.4B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
17%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Other Current Liabilities
₹11.8B
CAGR 3-Years
12%
CAGR 5-Years
17%
CAGR 10-Years
2%
No Stocks Found

Astrazeneca Pharma India Ltd
Glance View

Market Cap
211.3B INR
Industry
Pharmaceuticals

AstraZeneca Pharma India Ltd., a pivotal name in the Indian pharmaceutical landscape, is an integral arm of the global biopharmaceutical titan, AstraZeneca PLC headquartered in Cambridge, UK. The company has woven itself into the fabric of healthcare by consistently delivering novel medicines designed to combat a range of illnesses that include oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory ailments. In India, AstraZeneca Pharma has carved out a reputation for not only introducing cutting-edge research and development capabilities but also adapting its global innovations to fit the unique demands of the local market. By leveraging a robust pipeline of therapeutic solutions, the company plays a crucial role in the intersection of healthcare and technology, aiming to improve patient outcomes through personalized medicine and bioscience-led innovations. The business model of AstraZeneca Pharma India is anchored in its commitment to research-driven innovation and strategic partnerships. Revenue streams are tightly interlinked with the company’s ability to successfully commercialize its extensive portfolio of patented medicines. AstraZeneca focuses on maintaining strong relationships with healthcare professionals and stakeholders, which are pivotal in driving prescriptions and ensuring the adoption of its novel therapies. Sales and distribution channels are fortified through collaborations with hospitals, pharmacies, and other healthcare providers, ensuring a broad reach across the country. The company continues to invest in its capabilities to educate and train medical professionals, thus enhancing its influence in the medical community and reinforcing its position as a market leader in providing life-saving medications.

ASTRAZEN Intrinsic Value
3 649.17 INR
Overvaluation 57%
Intrinsic Value
Price ₹8 452

See Also

What is Astrazeneca Pharma India Ltd's Other Current Liabilities?
Other Current Liabilities
2.2B INR

Based on the financial report for Dec 31, 2025, Astrazeneca Pharma India Ltd's Other Current Liabilities amounts to 2.2B INR.

What is Astrazeneca Pharma India Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
4%

Over the last year, the Other Current Liabilities growth was 43%. The average annual Other Current Liabilities growth rates for Astrazeneca Pharma India Ltd have been 15% over the past three years , 13% over the past five years , and 4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett